Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.71 |
| ▸ | TGM2 | P21980 | 1/20 | 0.66 |
| ▸ | IMPDH2 | P12268 | 7/20 | 0.65 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.65 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.62 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.62 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.62 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.62 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.62 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.61 |
| ▸ | KRAS | P01116 | 2/20 | 0.60 |
| ▸ | GSK3A | P49840 | 1/20 | 0.60 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.60 |
| ▸ | PNP | P00491 | 1/20 | 0.60 |
| ▸ | HINT1 | P49773 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytarabine 5'-Phosphate SCHEMBL249411 | 0.97 | NT5E (0.67) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| Cytarabine 5'-Phosphate SCHEMBL28224063 | 0.97 | NT5E (0.67) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL8655976 | 0.97 | NT5E (0.67) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| SCHEMBL18281060 | 0.95 | NT5E (0.71) | NT5ETGM2IMPDH2IMPDH1P2RY2 | |
| SCHEMBL1983921 | 0.95 | NT5E (0.71) | NT5ETGM2IMPDH2IMPDH1P2RY2 | |
| SCHEMBL16245474 | 0.93 | TGM2 (0.62) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL13497991 | 0.91 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL21803790 | 0.91 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL20276926 | 0.91 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL20677331 | 0.91 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4696705-A1 | ENGINEERED TRANSCRIPTION REPRESSORS AND USES THEREOF | Fondazione Telethon ETS (IT) | 2026-02-18 | — | — | EP | claimed |
| EP-4696705-A1 | ENGINEERED TRANSCRIPTION REPRESSORS AND USES THEREOF | Fondazione Telethon ETS (IT) | 2026-02-18 | — | — | EP | disclosed |
| US-12503495-B2 | Treatment of myotonic dystrophy | ASSOCIATION INSTITUT DE MYOLOGIE (FR) | 2025-12-23 | — | — | US | disclosed |
| US-12480126-B2 | Modulation of dystrophia myotonica-protein kinase (DMPK) expression | IONIS PHARMACEUTICALS, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| WO-2025233286-A2 | THE USE OF ARCA AND 2'O-METHYL TRANSFERASE ENZYME TO PRODUCE CAP1 STRUCTURE OF 5' MRNA CAP | THERMO FISHER SCIENTIFIC BALTICS UAB (LT) | 2025-11-13 | — | — | WO | disclosed |
| US-12397065-B2 | Nucleic acids, peptides and methods | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2025-08-26 | — | — | US | disclosed |
| CN-119587480-A | Compositions and methods for treating ocular disorders | 视尔普斯眼科公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119580855-A | Nanocrystalline metal creep property prediction method based on molecular dynamics simulation | 河海大学 | 2025-03-07 | — | — | CN | disclosed |
| US-20250066792-A1 | COMPOUNDS AND METHODS FOR MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| CN-115066232-B | Compositions and methods for treating ocular disorders | 视尔普斯眼科公司 | 2024-12-10 | — | — | CN | disclosed |
| WO-2022096768-A1 | METHOD FOR PRODUCING MIRNA LIBRARIES FOR MASSIVE PARALLEL SEQUENCING | UNIVERSIDAD DE GRANADA (ES) | 2022-05-12 | — | — | WO | disclosed |
| EP-3995580-A2 | COMPOUNDS AND METHODS FOR MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| US-20220133774-A1 | MODULATION OF MICRORNAS AGAINST MYOTONIC DYSTROPHY TYPE 1 AND ANTAGONISTS OF MICRORNAS THEREFOR | UNIV VALENCIA (ES) | 2022-05-05 | — | — | US | disclosed |
| EP-3371207-B1 | NUCLEIC ACIDS, PEPTIDES AND METHODS | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2022-04-27 | — | — | EP | disclosed |
| US-20220096518-A1 | COMPOSITIONS AND METHODS FOR CANCER THERAPY | AIM IMMUNOTECH INC. (US) | 2022-03-31 | — | — | US | disclosed |
| US-20220062321-A1 | METHODS FOR IMPROVING EXERCISE TOLERANCE IN MYALGIC ENCEPHALOMYELITIS PATIENTS | AIM IMMUNOTECH INC. (US) | 2022-03-03 | — | — | US | disclosed |
| US-11255848-B2 | Polymer-nanostructure composition for selective molecular recognition | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-02-22 | — | — | US | disclosed |
| EP-2663640-B1 | NUCLEIC ACID MOLECULE HAVING BINDING AFFINITY TO A TARGET MOLECULE AND A METHOD FOR GENERATING THE SAME | APTARION BIOTECH AG (DE) | 2020-11-04 | — | — | EP | disclosed |
| US-9976145-B2 | Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same | NOXXON PHARMA AG (DE) | 2018-05-22 | — | — | US | disclosed |
| US-20140350088-A1 | Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same | APTARION BIOTECH AG (DE) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12480126-B2 | Modulation of dystrophia myotonica-protein kinase (DMPK) expression | DMPK, HNRNPK, MYLK2 | NT5E 3685/4885TGM2 2872/4885IMPDH2 3195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.